Resources & Support | PANHEMATIN® (hemin for injection)

Resources & Support

An AIP Diagnosis can be Challenging

For patients with Acute Intermittent Porphyria (AIP), having additional support can help alleviate some of the stress associated with a rare disease diagnosis.

RRD Patient Solutions Financial Support Online Resources

RRD Patient Solutions

Recordati Rare Diseases Patient Solutions (RRD PS) is here to support your patients treated with PANHEMATIN.
When your patients enroll in RRD PS, they will have access to a dedicated team. A completed RRD Patient Solutions Opt-In Form is required for a patient to enroll in RRD Patient Solutions services.

A portrayal of a customer service representative
Actor portrayal.

RRD PS Case Managers

  • Benefit Investigation. Help determine whether the patient’s insurance will cover PANHEMATIN.
  • Prior Authorization and Appeals. Help facilitate the prior authorization process by determining requirements, provide plan-specific paperwork, and following up on the final decision.
  • Financial Assistance for Eligible Patients. Provide support for eligible patients and resources to alternative funding solutions to those who are underinsured or uninsured.

Therapeutic Education Managers (TEMs)

  • Education. Provide education on AIP and and PANHEMATIN treatment.
  • One-on-one Support. Help patients create a personalized AIP Attack Treatment Plan to help navigate their treatment journey.
  • Resources. Connect patients with available educational resources on AIP.
Enroll Today
TEMs are paid to provide educational services on behalf of Recordati Rare Diseases. They don’t provide medical advice. Patients should always talk to their healthcare provider about any healthcare needs.

Financial Support

RRD PS Financial Assistance Programs are designed to provide support for eligible patients who wouldn't be able to access PANHEMATIN otherwise.

A portrayal of a woman on her laptop
Patient portrayal.

Copay Assistance Program

RRD PS Copay Assistance Program may be able to help with eligible patients’ treatment costs and out-of-pocket costs, such as copayments and coinsurance, if they meet program requirements.*

Patient Assistance Program

RRD PS Patient Assistance Program provides financial support for eligible patients who have limited access to treatment due to insurance issues and/or financial challenges.

Enroll Today
* The RRD PS Co-Pay Program (the “Program”) is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance programs. The Program is not valid where prohibited by law, and savings may vary depending on patients’ out-of-pocket costs. Recordati Rare Diseases reserves the right to modify or terminate the Program at any time without notice. Patients will receive all Program details upon registration. Approval is not guaranteed. Additional terms and conditions apply.

Recordati Rare Diseases Patient Solutions help is available to you and your patients

You can reach us at 1-‍866‍-20‍9-760‍4, or fax 1-‍866‍-209‍-7599. Monday through Friday, between 8:00 AM and 8:00 PM ET.

Click to Call

Online Resources

For Clinicians

Dosing Calculator

An interactive formula tool to calculate a PANHEMATIN dose.

Get Started

Dosing & Administration Video

A step-by-step video describing the preparation, reconstitution, and administration of PANHEMATIN, including list of needed infusion supplies.

Watch Video

Dosing & Administration Guide

A step-by-step guide to preparing, reconstituting, and administering PANHEMATIN, including list of needed infusion supplies.

Download Guide

AIP Medical Emergency Letter

For clinicians to fill out so patients have it on hand in case they need to seek emergency care.

Get Started

Order PANHEMATIN

Everything you need to know about the order and delivery of PANHEMATIN.

Learn More

Letter of Appeal Template

A sample letter to assist with insurance appeals.

Download Template

For Patients

AIP Discussion Guide

For your patients to share with their families and help start a conversation around understanding AIP.

Download Guide

AIP Attack Plan

For your patients to fill out so they are prepared with key action steps and emergency contact information.

Download Plan

RRD PS Opt-In Form

For your patients to complete when they are prescribed PANHEMATIN so they can be contacted by a RRD PS support team member to answer their questions about treatment with PANHEMATIN. 

Learn More

Advocacy Support

The American Porphyria Foundation

The American Porphyria Foundation (APF) educates physicians and the general public, raises funds for research, and advocates for better policy and patient care.

Visit Site

The National Organization for Rare Diseases

The National Organization for Rare Diseases (NORD) is a federation of voluntary health organizations dedicated to helping people with rare “orphan” diseases.

Visit Site

The Porphyrias Consortium

The Porphyrias Consortium, part of the Rare Diseases Clinical Research Network founded by the NIH, benefits patients and physicians by enabling a large-scale collaborative effort to develop new strategies and methods for diagnosis, treatment, and prevention of illness and disability resulting from rare disorders.

Visit Site

The United Porphyrias Association

The United Porphyrias Association is committed to improving the quality of life of the porphyria community, and is focused on advancing disease awareness, research, and therapies for all the porphyrias.

Visit Site

INDICATION AND USAGE

PANHEMATIN is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.

Limitations of Use

  • Before administering PANHEMATIN, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days).
  • Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. PANHEMATIN therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. PANHEMATIN is not effective in repairing neuronal damage.

IMPORTANT SAFETY INFORMATION

PANHEMATIN is contraindicated in patients with known hypersensitivity to this drug.

See More +

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

PANHEMATIN is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.

Limitations of Use

  • Before administering PANHEMATIN, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days).
  • Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. PANHEMATIN therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. PANHEMATIN is not effective in repairing neuronal damage.

IMPORTANT SAFETY INFORMATION

PANHEMATIN is contraindicated in patients with known hypersensitivity to this drug.

Risk of Phlebitis: Phlebitis is possible. Utilize a large arm vein or a central venous catheter for administration to minimize the risk of phlebitis.

Iron and Serum Ferritin: Elevated iron and serum ferritin may occur. Monitor iron and serum ferritin in patients receiving multiple administrations of PANHEMATIN.

Anticoagulant Effects: PANHEMATIN has transient and mild anticoagulant effect. Avoid concurrent anticoagulant therapy.

Renal Effects: Reversible renal shutdown has been observed with an excessive hematin dose (12.2 mg/kg in a single infusion). Strictly follow recommended dosage guidelines.

Transmissible Infectious Agents: PANHEMATIN may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product.

The most common adverse reactions (>1% of patients) are headache, pyrexia, infusion site reactions, and phlebitis.

To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions: Avoid CYP inducing drugs such as estrogens, barbituric acid derivatives and steroid metabolites which induce δ-aminolevulinic acid synthetase 1 (ALAS1) through a feedback mechanism.

PANHEMATIN® (hemin for injection), for intravenous infusion only, is available as powder for reconstitution in 350 mg vials.

Please see full Prescribing Information.